Vertex Pharmaceuticals (VRTX) Operating Expenses (2009 - 2026)

Vertex Pharmaceuticals' Operating Expenses history runs 18 years deep, the most recent figure standing at $1.8 billion for Q1 2026.

• In Q1 2026, Operating Expenses fell 13.61% year-over-year to $1.8 billion; the TTM figure through Mar 2026 stood at $7.5 billion (down 36.36% YoY), while the FY2025 annual figure was $7.8 billion, down 30.44% from the prior year.
• Operating Expenses for Q1 2026 stood at $1.8 billion, down from $2.0 billion in the prior quarter.
• The five-year high for Operating Expenses was $6.2 billion in Q2 2024, with the low at $1.1 billion in Q1 2022.
• The 5-year median for Operating Expenses is $1.6 billion (2023), against an average of $1.9 billion.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses surged 319.98% in 2024, then tumbled 70.56% in 2025.
• Vertex Pharmaceuticals' Operating Expenses stood at $1.3 billion in 2022, then increased by 20.49% to $1.5 billion in 2023, then grew by 23.33% to $1.9 billion in 2024, then climbed by 5.2% to $2.0 billion in 2025, then slipped by 6.82% to $1.8 billion in 2026.
• Business Quant data shows VRTX's Operating Expenses at $1.8 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.9 billion in Q3 2025.